Search

for
Search:

Research

5 / 1000+ results

research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders

45 citations , July 2025 in “Journal of Medicinal Chemistry”

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

research Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors

September 2021 in “World journal of urology”

The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.

research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia

6 citations , September 2018 in “Journal of Dermatological Treatment”

This review examines the FDA's 510(k) approval process for low-level laser therapy devices used in treating androgenetic alopecia and reports no new clinical findings.

research FDA Reports of Alopecia as an Adverse Event to Isotretinoin

5 citations , July 2019 in “Journal of Cutaneous Medicine and Surgery”

Isotretinoin may cause hair loss, especially in women and young adults.

research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches

July 2025 in “Scientific Reports”

In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.

View more "fda submission" in research →

Community Join

5 / 769 results

community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?

in Chat 4 upvotes 4 months ago

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

community Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)

44 upvotes 3 months ago

Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.

community Recent Study finds Laser caps are more effective than 5% minoxidil for AGA

in Research/Science 124 upvotes 2 years ago

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

community Clascoterone might be the Finasteride for female pattern hair loss.

9 upvotes 2 months ago

Clascoterone, a topical anti-androgen, shows promise for treating female pattern hair loss without systemic side effects, offering a potential alternative to minoxidil. It could also benefit men who experience side effects from finasteride.

community Why isn’t Clascoterone being discussed more?

5 upvotes 1 week ago

Clascoterone is seen as a promising alternative for those who can't tolerate finasteride due to side effects like reduced libido and anxiety. Users discuss using topical finasteride and minoxidil for hair maintenance and consider Clascoterone as a potential future treatment.

View more "fda submission" in community →

Learn

— no results

Try a deeper search in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →